| COMPLETE
EN BLOC URINARY EXENTERATION FOR SYNCHRONOUS MULTICENTRIC TRANSITIONAL
CELL CARCINOMA WITH SARCOMATOID FEATURES IN A HEMODIALYSIS PATIENT
(
Download pdf )
TIBERIO M. SIQUEIRA
JR, EVANDRO FALCAO, TIBERIO M. SIQUEIRA
Memorial
Sao Jose Hospital, Recife, Pernambuco, Brazil
ABSTRACT
The
incidence of transitional cell carcinoma (TCC) in patients submitted to
hemodialysis is low. The presence of TCC with sarcomatoid features in
this cohort is even scarcer. Herein, we describe a very rare case of synchronous
multicentric muscle invasive bladder carcinoma with prostate invasion
in a hemodialysis patient, submitted to complete en bloc urinary exenteration.
Key
words: hemodialysis; urologic neoplasms; carcinosarcoma; bladder;
surgery
Int Braz J Urol. 2006; 32: 560-2
CASE REPORT
A
58 years-old white obese man, submitted to a hemodialysis program due
to diabetic nephropathy, was referred to our department because of painless
macroscopic hematuria.
Ultrasound and cystoscopy revealed multiple
pediculated and sessile lesions in different parts of the bladder. Pre-operative
computed tomography (CT) scan showed no extravesical dissemination or
node enlargement.
The patient was submitted to a deep transurethral
resection of bladder tumor (TURb) in part of the visible masses, but not
all due to its extent. Pathologic examination showed high-grade urothelial
tumor, with invasion of the lamina propria layer only.
Based on the pathological report, the patient
was submitted to en bloc urinary exenteration associated to extended pelvic
lymphadenectomy (Figure-1). Operative time, blood loss and hospital stay
were 300 minutes, 770 mL and 5 days, respectively. No complications were
observed.
Final pathology evidenced high-grade muscle
invasive bladder carcinoma with extravesical invasion to adipose tissue
and bladder neck. Prostate invasion by the urothelial tumor was observed,
presenting sarcomatoid features (Figure-2). Surgical margins, kidneys,
ureters and nodes were free of tumor. No chemoteraphy treatment was administered.
On postoperative month 6, CT scan showed
multiple lesions in both lungs and brain. Pleural biopsy evidenced bladder
tumor metastasis. Six days later, the patient died of metastasis complications.
COMMENTS
It
is well known that uremic patients have a higher risk to develop cancer,
in which the most common types are the urological ones (1).
Recently, Wu et al. (2) reported the largest
experience ever published with hemodialysis patients presenting TCC. In
all 30 cases, the initial diagnosis presented gross hematuria as a cause.
According to final surgical status, the patients were divided in 6 different
groups. Groups 1 and 2 had total urinary exenteration (11 cases). Groups
3 and 4 had uni or bilateral nephroureterectomy with bladder cuff excision
(13 cases). Group 5 had only TURb and group 6 with one case of radical
cystectomy and ileal conduit.
The authors observed 100% incidence of recurrence
rate in the patients of group 2, leading to a stepwise total exenteration.
Likewise, the recurrence rate in groups 3,4 and 5 were 2.3, 1.7 and 1.8
times, respectively. Finally, the treatment administered to patients in
group 6 was considered not ideal, due to the inability in monitoring recurrences.
The conclusion was that no matter what the tumor grade, stage or location,
the treatment of choice for hemodialysis patients presenting TCC is total
urinary exenteration.
In our case, every definitive forms of treatment
were discussed with the patient. Besides that, the low residual urinary
output led us choose the total “en bloc” urinary exenteration.
For our surprise, final pathology showed a MIBC with sarcomatoid features
and prostate invasion.
No chemotherapy was prescribed, based on
the final pathological report and the patient’s clinical status.
The rapid progression to lungs and brain metastasis, show the aggressiveness
of the tumor and made us wonder if chemotherapy would avoid this final
course.
This case corroborates with the need to
evaluate every patient in hemodialysis presenting hematuria in order to
diagnose TCC. To the best of our knowledge, this is the first report of
synchronous multicentric MIBC with sarcomatoid features and prostatic
invasion that is treated by total “en bloc” urinary exenteration.
Depending on clinical status, chemotherapy should be considered.
ACKNOWLEDGEMENT
To
Dr. Adonis Carvalho for pathological examination and manuscript review.
CONFLICT OF
INTEREST
None
declared.
REFERENCES
- Giacnochi F, Formica M, Quarello F, Bonello F, Piccoli G: High incidence
of cancer in uremic patients. Clin Nephrol. 1985; 23: 265-6.
- Wu CF, Shee JJ, Ho DR, Chen WC, Chen CS: Different treatment strategies
for end stage renal disease in patients with transitional cell carcinoma.
J Urol. 2004; 171: 126-9.
____________________
Accepted after revision:
February 20, 2006
________________________
Correspondence address:
Dr. Tibério M Siqueira Jr
Av. Agamenon Magalhães, 4775 / 201
Recife, PE, 50070-160, Brazil
E-mail: tiberiojr@uol.com.br |